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Abstract
Purpose: The use of stably integrated reporter gene imaging provides a manner to monitor the in vivo fate of engrafted
cells over time in a non-invasive manner. Here, we optimized multimodal imaging (small-animal PET, Cerenkov
luminescence imaging (CLI) and bioluminescence imaging (BLI)) of mesenchymal stem cells (MSCs), by means of the human
sodium iodide symporter (hNIS) and firefly luciferase (Fluc) as reporters.
Methods: First, two multicistronic lentiviral vectors (LV) were generated for multimodal imaging: BLI, 124I PET/SPECT and CLI.
Expression of the imaging reporter genes was validated in vitro using 99mTcO4
2 radioligand uptake experiments and BLI.
Uptake kinetics, specificity and tracer elution were determined as well as the effect of the transduction process on the cell’s
differentiation capacity. MSCs expressing the LV were injected intravenously or subcutaneously and imaged using small-
animal PET, CLI and BLI.
Results: The expression of both imaging reporter genes was functional and specific. An elution of 99mTcO4
2 from the cells
was observed, with 31% retention after 3 h. After labeling cells with 124I in vitro, a significantly higher CLI signal was noted in
hNIS expressing murine MSCs. Furthermore, it was possible to visualize cells injected intravenously using BLI or
subcutaneously in mice, using 124I small-animal PET, CLI and BLI.
Conclusions: This study identifies hNIS as a suitable reporter gene for molecular imaging with PET and CLI, as confirmed
with BLI through the expression of Fluc. It supports the potential for a wider application of hNIS reporter gene imaging and
future clinical applications.
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Introduction
The development of imaging reporter genes is of great
importance to the field of molecular imaging, as their encoded
proteins can permit longitudinal non-invasive imaging of biolog-
ical processes at the cellular and subcellular level.
One of these imaging reporter genes encodes for the well-
characterized human sodium iodide symporter (hNIS) [1]. hNIS is
situated in the basolateral membrane of thyroid follicular cells, as
well as other tissues such as the stomach mucosa, salivary glands
and the lactating mammary gland. hNIS is an intrinsic plasma
membrane glycoprotein with 13 transmembrane domains that
mediates the first step in the formation of thyroid hormones by the
transport of iodide into the thyroid follicular cells against a
concentration gradient [1]. Furthermore, hNIS is able to transport
radioactive forms of iodide, as well as other anions such as
technetium pertechnetate (99mTcO4
2) [2]. Due to its relatively low
endogenous expression in extrathyroidal tissues, the wide avail-
ability of FDA-approved radioactive probes and the experience
with hNIS imaging, hNIS satisfies most of the criteria to be a
suitable reporter gene for imaging purposes [3]. Furthermore,
hNIS is a human protein and its use as an imaging reporter gene
will therefore not evoke immunological responses [4].
Exogenous expression of hNIS can be applied for non-invasive
and nuclear imaging of grafted cells. This can lead to a better
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understanding of stem cell homing, and assist in further applying
and developing stem cell-based therapies.
Mesenchymal stem cells (MSCs) are non-hematopoietic mul-
tipotent stem cells with an innate ability to differentiate towards
multiple mesenchymal lineages [5,6]. These cells appear to be
good candidates for clinical use; they can be expanded easily in
vitro and lack immunogenicity [7]. MSCs also possess immune
modulating properties, through the inhibition of immune cell
function and proliferation, and their use as immunomodulators is
being explored clinically [8]. Besides their role in tissue
regeneration, MSCs have significant trophic effects on endogenous
(stem) cells [9]. Furthermore, they have also been proven to
migrate towards multiple tumors in vivo, which renders them good
candidates as delivery vehicles for antitumor therapy [10–12].
Because of these characteristics, the interest in MSCs for clinical
applications has increased over the past years. As such, MSCs
have been used in several clinical phase I and phase II studies
concerning acute myocardial infarction [13], but the most
promising results have been obtained in human graft-versus-host
disease and allograft rejection studies [14–18].
To further improve stem cell-based treatments, cellular homing
as well as survival after engraftment needs to be studied in greater
detail. Imaging reporter genes can play an important role in the
non-invasive longitudinal follow-up of grafted cells. In the present
work, we optimized lentiviral vector (LV) transduction of murine
MSCs, inducing the expression of the imaging reporter genes
firefly luciferase (Fluc) for bioluminescence imaging and hNIS for
emission tomography (PET/SPECT) and Cerenkov luminescence
imaging (CLI).
CLI uses Cerenkov radiation for molecular imaging. Cerenkov
radiation is an electromagnetic radiation emitted when a charged
particle travels at a speed beyond the speed of light in a dielectric
medium. The upper limit on speed (c), is the speed of light in a
vacuum, but in a particular medium the speed of light is a fraction
of c (in water ,0.75), and positrons from PET isotopes can be
emitted at speeds higher than these values. The charged particle
travels through the medium and thereby temporarily displaces the
electrons in the medium. While returning to their ground state, the
electrons will emit visible light photons that can be detected using
a BLI system [19,20]. It is thus possible to image certain PET
Table 1. Vector constructs used for gene transfer.
Vector type Expression cassette Cell type
LV LV_hNIS HEK293T
LV_eGFP
Bicistronic LV LV_hNIS-T2A-Fluc HEK293T
LV_hNIS-T2A-eGFP
LV_Fluc-T2A-eGFP
Multicistronic LV LV_hEF1a-3flagFluc-T2A-hNIS-IRES-PuroR MSCs
LV_EF1a-3flagFluc-IRES-PuroR
doi:10.1371/journal.pone.0094833.t001
Figure 1. Diagram illustrating the steps involved in this study. Overview of the lentiviral vector constructs used to induce reporter gene
expression and the experiments performed with these respective vectors.
doi:10.1371/journal.pone.0094833.g001
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radionuclides via an optical system with high sensitivity and short
scanning times.
Here, the longitudinal expression of these imaging reporter
genes was evaluated both in vitro and in vivo.
Materials and Methods
Cell culture
HEK293T cells were used for testing the functionality of the
different vectors described below. Cells were cultured under
normal oxygen conditions in a 5% CO2 humidified incubator at
37uC. Growth medium consisted of Dulbecco’s modified eagle
medium (DMEM, Gibco, Invitrogen, Carlsbad, CA, USA), 10%
fetal bovine serum (FBS; Lonza BioWhittaker, Basel, Switzerland)
and 1% Penicillin/Streptomycin (Gibco).
Murine MSCs from C57Bl/6 mice were obtained from the lab
of Prof. dr. D Prockop, Tulane University, USA [21]. Cells were
cultured in a 5% CO2 humidified incubator under normoxic
conditions at 37uC in growth medium containing Iscove’s
Modified Dulbecco’s Medium (IMDM, Gibco), 10% FBS, 10%
horse serum (Biochrom, Berlin, Germany), 1% L-glutamine
(Gibco) and 1% penicillin/streptomycin.
Lentiviral vector optimization and transduction
For the optimization of the final multicistronic LV construct,
different vector types and constructs were generated and tested,
(for an overview see Table 1 and Fig. 1). LV constructs carrying a
cytomegalovirus immediate early (CMVie) promoter driving hNIS
or enhanced green fluorescent protein (eGFP) as a control
(LV_hNIS and LV_eGFP, respectively) were used at first in
HEK293T cells as a proof-of-principle to demonstrate hNIS
functionality. Subsequently, bicistronic LV were generated,
combining hNIS with alternative imaging reporter modules where
a CMVie promoter drives hNIS and Firefly luciferase (Fluc, for
bioluminescence imaging) or hNIS and eGFP (fluorescence)
coupled by a Thosea asigna virus 2A (T2A) sequence, LV_Fluc-
T2A-hNIS and LV_eGFP-T2A-hNIS, respectively. As a control, a
LV was included encoding both eGFP and Fluc coupled by a T2A
sequence, LV_eGFP-T2A-Fluc [22]. In parallel, we determined
the ideal promoter for efficient MSC transcription, employing a
LV that drives eGFP from different promoters, such as human
elongation factor 1a (EF1a), human Cyclophilin A (CypA), or viral
Spleen focus forming virus LTR (SFFV), and CMVie. These LV
were referred to as LV_hEF1a-eGFP, LV_CypA-eGFP,
LV_SFFV-eGFP, LV_CMVie-eGFP, respectively. MSCs were
transduced with the respective vectors using a protocol as reported
earlier [23]. eGFP fluorescence was monitored using fluorescence
activated sorting (FACS) and on day 37, the 5% brightest
population was isolated from each condition to overcome the lack
of puromycin resistance in the expression cassettes. Long-term
eGFP expression was monitored using FACS until 60 days. Results
are given as total fluorescence (fraction of total cells that are
fluorescent6mean fluorescence intensity).
Finally, a multicistronic LV carrying the hEF1a promoter to
drive triple flag tagged firefly luciferase (3flagFluc), a T2A
sequence, the human sodium iodide symporter (hNIS), an internal
ribosomal entry site (IRES), and a puromycin resistance gene
(PuroR), LV_hEF1a-3flagFluc-T2A-hNIS-IRES-PuroR was test-
ed. As a control, the same vector lacking hNIS was used,
LV_EF1a-3flagFluc-IRES-PuroR. For the sake of clarity, MSCs
transduced with the LV_EF1a-3flagFluc-T2A-hNIS-IRES-PuroR
will be referred to as Fluc-hNIS expressing MSCs. MSCs
transduced with the EF1a-3flagFluc-IRES-Puro LV, will be
referred to as Fluc expressing MSCs.
To create stable cell lines, cells were seeded into medium
containing serial dilutions of LV and cells were incubated for
48 hours. For the selection of transduced cells, 2 mg/mL
puromycin (Merck Millipore, Darmstadt, Germany) was added
to the growth medium, and cells were maintained under this
condition.
In vitro radiotracer uptake experiments
Cells were plated in triplicate in 24-well plates at a density of 105
cells per well in normal growth medium, and kept under standard
incubation conditions. After 24 hours, cells were washed with PBS
and incubated with 250 mL of pertechnetate (99mTcO4
2) tracer
solution (0.74 MBq/mL in DMEM; Gibco) for different periods
(n = 3). All in vitro data are shown as decay-corrected values.
After incubation, cells were washed 3 times with phosphate
buffered saline (PBS; Gibco), and tracer concentration in the cell
fraction was measured using a gamma counter (Perkin Elmer,
Waltham, MA, USA). Uptake values were corrected for the cell
number in the according samples, as measured using a
nucleocounter system (Chemometec, Allerød, Denmark).
The elution of 99mTcO4
2 initially taken up by the cells was
measured by incubating the cells for one hour with 99mTcO4
2
(0.74 MBq/mL), washing the cells and incubating them on tracer-
free DMEM for varying periods. The activity in the cells, the
supernatant and the elution medium was measured and elution
rates were calculated (n= 3).
Figure 2. Results of uptake experiments with 99mTcO4
2 in HEK293T cells after the induction of hNIS expression. Uptake ratios resulting
from the transduction with a unicistronic LV (b) and a bicistronic LV (c). Significantly higher uptakes were observed in cells expressing hNIS. **:
p,0.01; ***: p,0.001; ****:p,0.0001.
doi:10.1371/journal.pone.0094833.g002
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A blocking experiment was performed with sodium perchlorate
(NaClO4) using three different concentrations solved in DMEM:
10, 25 and 50 mM. The cells were incubated with the blocking
solutions containing the tracer (0.74 MBq/mL 99mTcO4
2 in
DMEM+ NaClO4) and activity in supernatant and cells was
measured using a gamma counter (n = 3).
Immunocytochemistry
To further confirm hNIS and 3flag expression in MSCs
transduced with the LV_EF1a-3flagFluc-T2A-hNIS-IRES-PuroR
and the LV_EF1a-3flagFluc-IRES-PuroR, immunofluorescent
stainings were performed. Cells were fixed using unifix for
20 min at 4uC, permeabilized with 0.05% Triton for 30 min at
room temperature (only in case of 3flag staining) and blocked with
10% normal donkey serum (Millipore) for 20 min at room
temperature. Cells were then incubated for two hours at room
temperature with the primary antibody diluted in PBS (hNIS 1/20
and flag 1/1000). Fluorescently labeled secondary antibody (1:500,
Alexa Fluor donkey anti-rabbit 488 or donkey anti-mouse 555,
Invitrogen) was incubated for 30 min at room temperature. Nuclei
were counterstained using DAPI and sections were mounted using
anti-fade mounting medium (Dako). Images were acquired using a
Nikon Eclipse 80 i Fluorescence microscope equipped with a
Nikon DS-2 MB Wc digital camera (Nikon Tokyo, Japan).
Stainings in which primary antibodies were omitted, were used as
a negative control.
Figure 3. Optimization of LV constructs and selection. Different promoters were tested with FACS (AU: arbitrary units) for eGFP expression in
MSCs transduced with different LV driven by different human or viral promoters (a). On day 38, FACS selection of the highest expressors was done
(red arrow on panel (a)), and this population was also monitored (b). 99mTcO4
2 uptake experiment in Fluc-hNIS or Fluc expressing MSCs with or
without puromycin selection (c). ****:p,0.0001.
doi:10.1371/journal.pone.0094833.g003
Multimodality Imaging of MSCs Using hNIS
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e94833
MSC differentiations
For adipogenic differentiations, cells were plated at a density of
10400 cells/cm2 in differentiation medium, containing aMEM
(Gibco), 10% FBS, 100 units of penicillin and 1000 units of
streptomycin, 1 mM dexamethasone, 10 mg/mL human insulin,
100 mM indomethacin and 25 mM methyl-isobutylxanthine (all
from Sigma-Aldrich, St Louis, MO, USA). Medium was changed
twice a week for 14 days (n = 3).
After 14 days, cells were rinsed with PBS, fixed using unifix
(Klinipath, Duiven, The Netherlands) for 20 minutes and stained
with fresh Oil red O solution (Sigma-Aldrich) for 10 minutes.
Images were taken using an inverted Zeiss axiovert microscope
(Hertfordshire, UK). For quantification of the lipid droplet
staining, the dye was extracted from the cells using 100% ethanol
and aliquots of 200 mL were transferred to a 96-well plate in
triplicate. Absorbance was measured at 450 nm using a Victor
1420 plate reader (Perkin Elmer).
To assess the effect on osteogenic differentiation capacity, MSCs
were seeded at 8400 cells/cm2 in normal growth medium and
allowed to become confluent for 48 h before adding osteogenic
differentiation medium. Differentiation medium contained
DMEM with sodium pyruvate, 10% FBS, 1% penicillin/
streptomycin, 50 mg/mL L-Ascorbic acid 2-phosphate sequimag-
nesium salt hydrate (AA-P; Sigma-Aldrich), 100 nM dexametha-
sone and 10 mM glycerol-2-phosphate disodium salt hydrate
(bGP). Medium was changed twice a week for 3 weeks (n = 3).
At day 21, cells were rinsed with PBS, fixed with ice-cold 70%
ethanol for 1 h and stained with Alizarin red S solution (Sigma) for
30 minutes. Images were taken using an inverted Zeiss axiovert
microscope. Afterwards, the dye was extracted from the cells using
a 10% cetylpiridinium chloride solution for 1 h. Aliquots of
200 mL were transferred to a 96-well plate in triplicate, and
absorbance was measured at 560 nm.
For chondrogenic differentiation, micromasses were generated
by seeding 20 mL droplets of cell suspension, each containing
200,000 cells, into separate wells of a 24-well plate. After
attachment for 3 hours expansion medium was added. The next
day, chondrogenic differentiation medium was added containing
DMEM/F12, 2.5% FBS, 100 nM dexamethasone, 16 ITS+,
50 mg/mL AA-P, 10 ng/mL Transforming Growth Factor-b
(TGF-b), 10 mM ROCK inhibitor and 40 mg/mL L-proline.
Every 2 days, medium was changed for 21 days (n = 3).
At day 21, cells were fixed using unifix and stained overnight
with Alcian Blue. The dye was extracted using 6M guanidine
HCL. The optical density of the extracted dye was measured at
595 nm in triplicates.
Figure 4. Validation of the multicistronic LV contruct. 99mTcO4
2 uptake kinetics in MSCs transduced with the two different multicistronic LV
constructs or wild type MSCs (a). Tracer elution from Fluc-hNIS expressing MSCs (b). The effect of different concentrations of NaClO4 on the uptake of
99mTcO4
2 in Fluc-hNIS expressing MSCs (c). Immunocytochemistry against hNIS on Fluc-hNIS expressing MSCs and DAPI (d), against 3flag in 3flagFluc-
hNIS expressing MSCs and DAPI (e) and negative control (f). Immunocytochemistry against 3flag in 3flagFluc expressing MSCs and DAPI (g) and
negative control (h).
doi:10.1371/journal.pone.0094833.g004
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Animal preparations
The protocols used in this study were approved by the Ethical
Committee of the KU Leuven (Permit Number: P145-2010).
For the intravenous injections, animals were anesthetized with
2% isoflurane (Isoflurane ISPH, Rothacher, Basel, Switzerland) in
100% oxygen, at a flow rate of 2 L/minute. Different cell numbers
of MSCs expressing Fluc-hNIS ranging from 10,000 to 1,000,000
were injected in the tail vein of healthy C57BL/6 mice, and
30 minutes after cell injections BLI was performed (n= 3).
For xenografts, both Fluc expressing MSCs (as a control), and
Fluc-hNIS expressing MSCs were injected subcutaneously in
anesthetized nude athymic mice (nu/nu) (n = 3). Fluc expressing
MSCs were injected on the left side of the body, whereas Fluc-
hNIS expressing cells were injected on the right side of the body.
Each mouse was injected with two different cell numbers per cell
line: 10,000 and 1,000,000 mixed with matrigel in a 1:1 ratio (BD
biosciences, New Jersey, USA).
Small-animal PET
The imaging of xenografts was performed on day 2 after
xenograft generation with 11 MBq of 124I (Perkin Elmer) per
mouse injected intravenously, with dynamic acquisitions of
90 minutes (n = 3) using a Focus 220 small-animal PET system
(Siemens Medical Solutions USA, Knoxville,TN). Images were
reconstructed with a maximum a posteriori (MAP) image
reconstruction algorithm, and analyzed in PMOD 3.0 (PMOD
technologies, Zu¨rich, Switzerland). Images were converted to
standardized uptake value (SUV) according to the standard
formula: SUV=Activity concentration in organ/[injected activi-
ty/animal weight].
A manually delineated volume of interest (VOI) was positioned
on the dynamic images over the Fluc-hNIS-expressing xenografts,
the control Fluc-expressing xenografts, and muscle tissue and the
brain as background tissues to generate time activity curves. Ratios
were calculated, comparing the signal in the Fluc-hNIS expressing
xenograft with background signals from control Fluc-expressing
xenografts, muscle tissue and brain.
Cerenkov luminescence imaging
For the in vitro CLI, cells were plated in triplicate in 24-well
plates at a density of 16105 cells per well in normal growth
medium, and kept under standard incubation conditions. After
24 hours, cells were washed with PBS and incubated with 250 mL
of tracer solution (0.74 MBq/mL 124I in DMEM; Gibco) for one
hour. Cells were washed 3 times with PBS, and placed in the BLI
chamber for the acquisition of 1 minute scans.
The in vivo CLI scans on xenografts were performed daily after
performing the 124I small-animal PET scans. CLI protocols were
executed as follows: animals were anesthetized using isoflurane in
100% oxygen, at a flow rate of 2 L/minute and positioned in the
BLI chamber without prior injection of D-luciferin. Images were
acquired using an IVIS 100 system (Perkin Elmer) and CLI
acquisition was done by acquiring one minute frames. The data
are reported as total photon flux (p/s) from a circular region of
interest (ROI). For all animals, first a daily CLI scan was
performed to measure the 124I distribution, and thereafter D-
luciferin was injected to measure the BLI signal intensity.
Bioluminescence imaging
For the in vitro BLI, cells were plated in triplicate in 24-well
plates at a density of 16105 cells per well in normal growth
medium, and kept under standard incubation conditions. After
24 hours, cells were washed with PBS and incubated with 250 mL
of D-luciferin (0.3 mg/mL; Promega, Benelux, Leiden, The
Netherlands). Cells were placed in the BLI chamber immediately
for the acquisition of 1 minute scans.
Animals were anesthetized with 2% isoflurane in 100% oxygen,
at a flow rate of 2 L/minute, after which D-luciferin, dissolved in
PBS (15 mg/mL), was injected intravenously (126 mg/kg body
weight). Images were acquired using an IVIS 100 system (Perkin
Elmer). Consecutive 1 minute frames were acquired until the
maximum signal intensity was reached. Each frame depicts the
bioluminescence signal intensity as a pseudocolor image superim-
posed on the gray-scale photographic image. The data are
reported as total photon flux (p/s) from a circular region of
interest (ROI). BLI signal intensity was monitored over 8 days
after xenograft generation.
For the quantification of BLI data in the mouse xenograft
model, values from according ROIs measured with CLI were
subtracted from the raw BLI ROI values to obtain specific BLI
signal intensities.
Statistical Analysis
Data are presented as mean 6 standard error of the mean
(SEM). For the uptake experiments using the unicistronic,
bicistronic and multicistronic vector after puromycin selection,
two-way analysis of variance (ANOVA) statistical tests were
performed with Bonferroni post-hoc tests. P-values,0.05 were
considered statistically significant. BLI and CLI data were tested
using an unpaired two-sided t-test after log transformation.
Differentiation analysis was performed using a one-way ANOVA
with Tukey post-hoc tests. The in vivo BLI data after intravenous
Figure 5. In vitro optical validation of the imaging reporter
genes. In vitro BLI (a) and CLI (b) of Fluc-hNIS expressing MSCs and Fluc
expressing MSCs. ****: p,0.0001.
doi:10.1371/journal.pone.0094833.g005
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injections were tested for gaussion distribution using the
Kolmogorov-Smirnov test and the Pearson’s R coefficient was
calculated as a measure of linear correlation. The in vivo xenograft
BLI data were evaluated using an unpaired t-test.
Data were processed using GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego, California, USA).
Results
hNIS is an efficient PET reporter in cell culture
Different LV vector types (Table 1, Fig. 1) were tested in
HEK293T cells for the optimization of the imaging reporter gene
expression. Stably hNIS expressing cells or control cells were
incubated with 99mTcO4
2. All transfections and transductions
(unicistronic LV and bicistronic LV, Fig. 2a,b) resulted in a 100-
fold to 300-fold higher uptake of tracer in cells expressing the
hNIS gene, compared to the controls (unicistronic LV: p,0.001;
bicistronic LV: p,0.0001).
EF1a as most potent promoter in MSC
The optimal promoter allowing the highest expression in MSCs
was assessed by comparing transduction of MSCs with LVs
encoding eGFP driven by human promoters (EF1a and CypA),
and viral promoters (CMVie, SFFV) (Fig. 3a,b). eGFP fluores-
cence was monitored with FACS, and there was a significantly
higher expression level in cells transduced with the EF1a
promoter, both without (Fig. 3a) and with sorting (Fig. 3b) of the
5 percent highest expressing cells (p,0.0001).
Puromycin selection increases reporter gene expression
Cells transduced with the multicistronic LV constructs using the
EF1a promoter were either kept on normal growth medium or on
growth medium with puromycin. To determine the effect of
puromycin selection of the expression of the imaging reporter
genes, the uptake of 99mTcO4
2 was assessed in both selected and
non-selected cells (Fig. 3c). A significantly higher uptake of the
radioligand was observed in Fluc-hNIS expressing MSCs upon
selection with puromycin (p,0.0001), compared to nonselected
and Fluc expressing MSCs.
Figure 6. Adipogenic, osteogenic and chondrogenic differentiation capacity of Fluc-hNIS expressing MSCs, Fluc expressing MSCs
and wild types. Extraction of the Oil red O dye following adipogenic differentiation measured at 490 nm (a). Extraction of the Alizarin red S dye
from differentiated osteoblast matrix, measured at 560 nm (b). Extraction of Alcian Blue dye from differentiated chondrocyte matrix, measured at
595 nm (c). *: p,0.05, **: p,0.01. Images of the Oil red O stainings (d,g,j), the Alizarin red S stainings (e,h,k) and the Alcian Blue stainings (f,I,l) for all
conditions: Fluc-hNIS, Fluc expressing cells and wild types.
doi:10.1371/journal.pone.0094833.g006
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Validation of hNIS expression in MSCs
MSCs were transduced with the multicistronic LV, and the
uptake kinetics of 99mTcO4
2 were assessed. Untransduced MSCs
and Fluc expressing MSCs were included as a negative control.
Decay-corrected uptake data (Fig. 4a) showed a strong increase in
uptake within the first 30 minutes of incubation in Fluc-hNIS
expressing MSCs, which was followed by a state of equilibrium
between the concentration inside and outside of the cells. A
significantly higher uptake (75 and 120 fold increase) was observed
in Fluc-hNIS expressing MSCs compared to either Fluc expressing
MSCs or wild type MSCs (p,0.001).
The elution of the tracer from the cells after initial uptake was
assessed in Fluc-hNIS expressing MSCs (Fig. 4b). After labeling,
cells were incubated in tracer-free medium and the relative elution
was calculated. A two-phased elution was observed, with a
substantial tracer elution occurring within 30 minutes, followed
by a slow elution of the tracer from the cells (p,0.001). After
3 hours, 31%61.3% of the initially bound tracer was still present
within the cells.
To determine the specificity of the uptake, the hNIS inhibitor
NaClO4 was used (Fig. 4c). Cells were incubated with the tracer
solved in the blocking solution and the uptake of 99mTcO4
2 was
measured. A significant decrease in the uptake of the tracer could
be observed (p,0.01) after the administration of the blocker.
Furthermore, the uptake of 99mTcO4
2 decreased with increasing
concentrations of NaClO4 (p,0.01). A decrease of 95%, 97.5%
and 98.6% was observed with concentrations of 10, 20 and 50 mM
of NaClO4, respectively. Data are represented as relative values
compared to incubation without perchlorate.
The expression of the imaging reporter genes was confirmed by
fluorescence immunocytochemistry. Fluc-hNIS expressing MSCs
and Fluc expressing MSCs were stained with primary antibodies
against hNIS and 3flag, and the expression of both reporter genes
was observed (Fig. 4d,e,g). Negative controls did not show an
aspecific staining or background signal (Fig. 4f,h).
In vitro BLI and CLI
In vitro BLI was performed to determine the expression of Fluc
in the cells after transduction with both the Fluc-hNIS LV and the
Fluc LV (Fig. 5a). Fluxes (in p/s) of log 5.6360.42 and 5.4960.9
were measured for the Fluc-hNIS and Fluc expressing cells,
respectively. Hence, there was no significant difference in Fluc
expression between both cell lines.
Both cell lines were also incubated with I124 and in vitro CLI was
performed (Fig. 5b). A significant difference was observed between
the fluxes of both cell lines (p,0.0001), with noted log values of
4.0560.02 for the Fluc-hNIS expressing cells, and 3.1560.06 for
the Fluc expressing cells.
MSC differentiations
Fluc-hNIS expressing MSCs, Fluc expressing MSCs and wild
type MSCs were differentiated towards the adipogenic, chondro-
genic and osteogenic lineage (Fig. 6).
Quantification of the extracted oil red O dye resulted in
following absorbance values (measured at 490 nm): 0.12, 0.17 and
0.19 for the Fluc-hNIS expressing MSCs, Fluc expressing MSCs
or wild type MSCs, respectively, resulting in a respective difference
of 35.3% and 7.4% compared to wild type MSCs (Fig. 6a,d,g,j). A
significant difference between cells transduced with the Fluc-hNIS
expressing MSCs and the two other cell lines was observed
(p,0.01).
Following osteogenic differentiation, quantification of matrix
mineralization resulted in following values after measuring the
Figure 7. BLI data of intravenously injected Fluc-hNIS expressing MSCs. An accumulation of cells could be visualized in the lungs. Different
cell numbers were injected, and total flux was measured. Both parameters were strongly correlated with an R2 of 0.97.
doi:10.1371/journal.pone.0094833.g007
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absorption of the samples at 560 nm: 2.49, 2.48 and 2.45 for the
Fluc-hNIS expressing MSCs, Fluc expressing MSCs or wild type
MSCs, respectively (Fig. 6b,e,h,k). Hence, no statistical difference
was obtained (p.0.05).
Alcian blue staining following chondrogenic differentiation was
quantified by dye extraction and measuring the absorption at
595 nm. The following values were obtained: 0.082, 0.072 and
0.074 for Fluc-hNIS expressing MSCs, Fluc expressing MSCs or
wild type MSCs, respectively (Fig. 6c,f,i,l). A statistically significant
increase in alcian blue dye incorporation within the chondrogenic
micromasses was observed in the Fluc-hNIS expressing MSCs
(p,0.05).
Imaging of intravenously injected MSCs using BLI
Different numbers of cells, ranging from 10,000 to 1,000,000,
were injected in the tail vein of healthy C57BL/6 mice, and
30 minutes after cell injection, either BLI or small-animal PET
was performed as a proof-of-principle for cell visualization. Using
BLI, a robust signal could be obtained in the lungs. The signal
intensity in the lungs increased when increasing cell amounts were
injected intravenously. A significant correlation between injected
amount of cells and total photon flux was obtained (p,0.01) with
an R2 value of 0.97 (Fig. 7 a,b).
Imaging of MSC xenografts using BLI, 124I small-animal
PET and CLI
MSCs expressing Fluc-hNIS or Fluc were engrafted subcuta-
neously in nude mice (n = 3), and imaged non-invasively using
BLI, Cherenkov imaging and 124I small-animal PET (Fig. 8). On
day 2 after cell injection, a 124I small-animal PET scan was
performed to visualize the engrafted cells expressing Fluc-hNIS. A
clear focus of increased tracer concentration was observed at the
site where the 1,000,000 MSCs expressing Fluc-hNIS were
injected. The xenograft resulting from the 10,000 cells could not
be detected on the small-animal PET images (Fig. 8d).
The xenograft to background ratio was 8 when comparing the
Fluc-hNIS expressing xenograft with muscle tissue. Five times
more radiotracer uptake was seen compared to the control
xenograft of 1,000,000 cells expressing Fluc. The brain showed 3
times less accumulation of the tracer compared to the Fluc-hNIS
expressing xenograft (Fig. 8a).
Figure 8. Visualization and follow-up of MSC xenografts. Fluc expressing MSCs were injected on the left flank of the body, and Fluc-hNIS
expressing MSCs were engrafted on the right side of the body. Xenografts of 10,000 injected cells were injected near the front, and 1,000,000 cells
were injected at the back for both conditions. Time activity curves of the ratios comparing the Fluc-hNIS expressing xenograft to background up
tissues, showing higher expressions in the Fluc-hNIS expressing xenograft compared to background signals (a,d). BLI was also performed to follow
the xenografts over time, with robust expression within all xenografts (b,e). CLI was performed to follow up the mice after 124I injection. The Fluc-hNIS
expressing MSCs could be visualized and monitored over time (c,f).
doi:10.1371/journal.pone.0094833.g008
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The BLI signal in xenografts derived from 1,000,000 cells was
significantly higher than in xenografts derived from 10,000 cells in
both MSC conditions (p,0.001). However, robust and specific
BLI signals could be obtained in all conditions over time, with no
decrease in signal being perceived in the monitored time span of 8
days (Fig. 8b,e). The BLI signals coming from the Fluc-hNIS
expressing MSCs and the Fluc expressing MSCs were within the
same range.
Two days after xenograft injection, 124I small-animal PET was
performed. In addition, 124I accumulation was monitored over
time using CLI for 8 days. (Fig. 8c,f). Accumulation of 124I was
detected in the thyroid, in the stomach and in the Fluc-hNIS
expressing xenograft situated on the right side of the body (red
circle). No signal was observed emanating from the bladder.
The Cherenkov signal detected in the xenograft expressing
Fluc-hNIS with 1,000,000 cells persisted over the 8 days of
measurements, decreasing according to the radioactive decay time
of 124I (T1/2: 4.2 days) as was shown after an exponential fit with
an R2 value of 0.63, yielding a half-life of 4.4 days.
Discussion
The emergence of stem cell therapies in regenerative medicine
urges the development of methodology for non-invasive tracking
of engrafted cells. The ability to image MSCs would be beneficial
as they hold clinical promise both due to their differentiation
capacity as well as their possibility to exert immune modulation
[5–7].
Stem cells expressing PET and SPECT imaging reporter genes
can be visualized longitudinally in vivo using nuclear medicine
imaging techniques. In this context, hNIS has been used already in
several studies both in the context of diagnosis and therapy (for
review [24]).
Tracking stem cells using imaging reporter genes requires the
insertion of a functionally active transgene into the stem cells to
obtain a functionally active reporter protein. LV are good
candidates because the genes of interest are introduced into the
genomic DNA of the host cells, and both dividing and non-
dividing cells can be targeted [25].
For optimal expression of our reporter genes, we first optimized
the transduction process of the MSCs as well as the promoter to
drive the final construct. Here, the EF1a promoter resulted in the
highest expression of eGFP, and was therefore chosen to drive our
reporter construct. The optimization of a promoter for transduc-
tions has been shown to be of great importance. Other groups
have also determined the optimal promoter for several purposes,
and in different cell types the EF1a promoter proved to be a
potent promoter with long-term expression on a high level
outperforming other commonly used promoters [26–31].
The introduction of genes into the host cells’ genetic material
can result in adverse effects resulting in the disruption of biological
processes. We evaluated the effect of the lentiviral transduction
process on MSCs. Although some statistically significant differ-
ences were observed, the biological relevance is likely nihil.
Therefore, we can conclude that lentiviral transduction with the
presently used imaging reporter gene constructs does not hamper
the differentiation capacity of the MSCs. Terrovitis et al have also
shown that ectopic expression of hNIS using lentiviral vectors does
not interfere with cell viability and function in cardiac-derived
stem cells [32]. This was also shown by Hu et al, who showed that
adenoviral vector transduction of the hNIS and rNIS gene had no
adverse effects on MSCs [33].
We demonstrated that hNIS and Fluc expression is functional
both in vitro and in vivo. In vitro, a robust radiotracer uptake of
99mTcO4
2 was obtained with a steady state already at 30 minutes
of incubation. The uptake was 75 or 120 times higher compared to
control cells. Furthermore, NaClO4, an inhibitor of hNIS, was
able to block the uptake of 99mTcO4
2 in a dose-dependent
manner.
However, a substantial elution from the cells was observed after
labeling, with 31%61.29% of the tracer being retained within the
cells after 3 hours. This might be due to the initial strong
concentration gradient that is generated while putting the cells
containing the tracer on tracer-free medium, leading to a rapid
washout of tracer molecules from the cells back into the medium,
until the gradient between the cells and the new supernatant
reaches a state of equilibrium. Furthermore, no organification of
the 99mTcO4
2 occurs after entry into the cells, as is the case in
thyroidal tissue, and therefore no trapping of the molecules takes
place. Nevertheless, 31% of the initially bound tracer molecules
remained trapped within the cells after 3 hours.
As a proof-of-principle, Fluc-hNIS expressing MSCs were
injected into the tail vein of healthy mice, and BLI signals in the
lungs were measured. Due to the first pass mechanism, cells
injected intravenously will first encounter the pulmonary capillary
bed and will transiently reside in the lung (pre)capillary bed. The
BLI signal correlated with the amount of cells injected, allowing
non-invasive detection of the cells.
Finally, long-term noninvasive multimodality imaging was
performed. For this purpose, 10,000 or 1,000,000 MSCs
expressing Fluc or Fluc-hNIS were injected subcutaneously on
the left flank and the right flank, respectively. All xenografts could
be visualized using BLI, and monitored over time with a robust
signal in all conditions. On day 2 after engraftment of the MSCs,
124I small-animal PET was performed, and the xenograft of
1,000,000 Fluc-hNIS expressing MSCs was clearly visible. The
injection site of 10,000 cells was not visible because of the partial
volume effect and the relatively higher background activity
resulting from hNIS expressing organs and circulating tracer.
The accumulation of 124I was also monitored using CLI. These
scans confirmed the information that was obtained with small-
animal PET, because the cerenkov signal detected in the xenograft
expressing Fluc-hNIS after injection of 1,000,000 cells persisted
over the 8 days of measurement, decreasing according to the
radioactive decay time of 124I (T1/2: 4.2 days) as shown by the
exponential fit with an R2 value of 0.63, yielding a half-life of 4.4
days. From these data we can conclude that the 124I is trapped
within the cells, and can be visualized using CLI. Besides the
xenograft, also the stomach and the thyroid accumulated 124I, due
to the endogenous hNIS expression in these tissues [1].
From these data we can conclude that imaging reporter genes
are a suitable tool for the non-invasive visualization of stem cells
after in vivo administration. Combining multiple imaging reporter
genes in the same construct enables us to perform multimodality
imaging to confirm the obtained data from one single imaging
modality. hNIS was used as an imaging reporter gene together
with Fluc. Using Fluc, longitudinal BLI can be performed as a
traditional optical imaging modality. BLI features a very high
sensitivity, almost no background signal, short scanning time, and
thus high throughput imaging.
hNIS is a human reporter gene reducing the chances of immune
responses against the reporter gene product. Furthermore, the
expression of hNIS is restricted to a limited number of tissues,
implying a relatively low background signal. hNIS can be used for
both therapeutic and diagnostic purposes. Imaging can be
performed with tracers for gamma cameras (99mTcO4
2), which
is widely available in every nuclear medicine department
worldwide. The physical advantages of a PET camera can also
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be used as we have shown by using 124I. Furthermore, the gene
can be used for therapeutic applications through the use of 131I.
When using multimodality imaging, it is also necessary to
consider both the advantages and the disadvantages of each
imaging modality. Optical imaging devices can be used for several
purposes such as fluorescence, bioluminescence and more recently
Cerenkov radiation. Here, CLI and BLI were used for cell
tracking, and higher signal intensity could clearly be seen in BLI
compared to CLI. Furthermore, BLI results in a very high signal to
noise ratio due to the low background signals. In contrast, CLI
images are noisy but CLI is a more translational optical imaging
system than BLI, because it is using tracer molecules that are often
already used in a clinical setting. This is particularly the case in
preclinical imaging, as not every institute is equipped with costly
dedicated small-animal nuclear imaging instruments.
For the imaging of radioactive tracer molecules, both CLI and
small-animal PET can be used. The optical imaging equipment
used for CLI allows a quick acquisition of data, and devices are
more available compared to small-animal PET devices due to the
lower costs of the hardware. However, PET imaging can also be
performed in a relatively quick way, and results in the generation
of tomographic images that are quantitatively more reliable.
Furthermore, despite the efforts that have been taken for 3D
optical imaging, there is a major lack of anatomical and
tomographic data. Also, PET does not generate anatomical
information, but this can be overcome relatively easily by co-
registration of PET images to anatomical computed tomography
(CT) images or magnetic resonance imaging (MRI) data. Indeed,
the development of hybrid systems combining PET and either CT
or MRI is an effective answer to this matter. Above all, PET is the
only modality that can be used in patients, and therefore has the
highest translational capacity of all the modalities.
For cell tracking studies, the combination of CLI and nuclear
imaging might form a translational bridge between optical imaging
and nuclear imaging modalities. Hence, the advantages of both
techniques can be combined: quantitative information in a
tomographic manner, and the high throughput and sensitivity of
the optical imaging. We here show that hNIS is a suitable reporter
gene for molecular imaging with PET and CLI. This reporter gene
can be used in humans and is therefore a good candidate in
translational studies.
Hence, future studies will include further reproducibility tests
and the application of this system in disease models.
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